Scholarlink

<p>This Summary of Research summarises results from the BE&#xa0;OPTIMAL (NCT03895203) and BE&#xa0;COMPLETE (NCT03896581) studies and their open-label extension, BE&#xa0;VITAL (NCT04009499). These phase&#xa0;3 studies looked at how well bimekizumab treatment worked in patients with psoriatic arthritis, and the safety of bimekizumab treatment, over the long term. Two patient groups were included in these studies: patients who had not previously been treated with biologic disease-modifying antirheumatic drugs (bDMARD-naïve; BE&#xa0;OPTIMAL) and patients who had a poor response or were intolerant to tumour necrosis factor (TNF) inhibitors (BE&#xa0;COMPLETE). These studies showed that the beneficial effects of bimekizumab treatment on patients’ symptoms reported at year&#xa0;1 of treatment were sustained up to 2&#xa0;years, regardless of whether patients were bDMARD-naïve or had previously had a poor response or intolerance to TNF inhibitors. Bimekizumab was well tolerated up to 2&#xa0;years. The data from this study may help clinicians and patients when they are making shared decisions on treatment options for psoriatic arthritis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月10日

查看全文
  • Philip J. Mease,
  • Joseph F. Merola,
  • Yoshiya Tanaka,
  • Laure Gossec,
  • Iain B. McInnes,
  • Christopher T. Ritchlin,
  • Robert B. M. Landewé,
  • Akihiko Asahina,
  • Barbara Ink,
  • Andrea Heinrichs,
  • Rajan Bajracharya,
  • Vishvesh Shende,
  • Jason Coarse,
  • Laura C. Coates

摘要

This Summary of Research summarises results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension, BE VITAL (NCT04009499). These phase 3 studies looked at how well bimekizumab treatment worked in patients with psoriatic arthritis, and the safety of bimekizumab treatment, over the long term. Two patient groups were included in these studies: patients who had not previously been treated with biologic disease-modifying antirheumatic drugs (bDMARD-naïve; BE OPTIMAL) and patients who had a poor response or were intolerant to tumour necrosis factor (TNF) inhibitors (BE COMPLETE). These studies showed that the beneficial effects of bimekizumab treatment on patients’ symptoms reported at year 1 of treatment were sustained up to 2 years, regardless of whether patients were bDMARD-naïve or had previously had a poor response or intolerance to TNF inhibitors. Bimekizumab was well tolerated up to 2 years. The data from this study may help clinicians and patients when they are making shared decisions on treatment options for psoriatic arthritis.